Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Saved in:
| Title: | Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. |
|---|---|
| Authors: | Welch M; Consano Clinical Research, San Antonio, TX, USA., Forst T; Clinical Research Services, Mannheim, Germany; Johannes Gutenberg University, Mainz, Germany., Jia W; Shanghai Sixth People's Hospital, Shanghai, China., Del Pino PO; Eli Lilly and Company, Indianapolis, IN, USA., Denning M; Eli Lilly and Company, Indianapolis, IN, USA., Wu WS; Eli Lilly and Company, Indianapolis, IN, USA., Li J; Eli Lilly and Company, Indianapolis, IN, USA., Liu R; Eli Lilly and Company, Indianapolis, IN, USA., Eifu M; Eli Lilly and Company, Indianapolis, IN, USA., Chen Y; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: chen_yanyun@lilly.com. |
| Corporate Authors: | ACHIEVE-2 Trial Investigators |
| Source: | Lancet (London, England) [Lancet] 2026 Jun 08. Date of Electronic Publication: 2026 Jun 08. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1474-547X |
|---|---|
| DOI: | 10.1016/S0140-6736(26)00800-7 |
